AlphaTON Capital Corp. has undergone a strategic transformation, rebranding from its previous identity as Portage Biotech Inc. While formerly engaged as a clinical-stage immuno-oncology firm, the company is now pivoting its operations towards a digital asset treasury model. This new focus primarily involves the acquisition and staking of Toncoin (TON). AlphaTON's ambition is to make significant investments in TON tokens, with the goal of building a long-term Toncoin treasury valued at approximately US$100 million.